Incyte Corporation (NASDAQ:INCY) insider David W. Gryska sold 3,915 shares of Incyte Corporation stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total value of $413,541.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Incyte Corporation (INCY) traded down $2.88 during mid-day trading on Friday, reaching $105.08. 1,741,891 shares of the company’s stock were exchanged, compared to its average volume of 1,783,900.

Incyte Corporation (NASDAQ:INCY) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.11. Incyte Corporation had a negative net margin of 10.90% and a negative return on equity of 12.91%. The business had revenue of $381.50 million for the quarter, compared to analysts’ expectations of $360.34 million. During the same quarter in the previous year, the firm posted $0.19 EPS. The business’s revenue for the quarter was up 41.6% compared to the same quarter last year. equities analysts anticipate that Incyte Corporation will post -1.01 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/david-w-gryska-sells-3915-shares-of-incyte-corporation-incy-stock/1676366.html.

Hedge funds have recently modified their holdings of the business. Oppenheimer Asset Management Inc. raised its holdings in Incyte Corporation by 9.9% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 27,147 shares of the biopharmaceutical company’s stock valued at $3,418,000 after acquiring an additional 2,455 shares during the period. Pinebridge Investments L.P. raised its holdings in Incyte Corporation by 122.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 74,590 shares of the biopharmaceutical company’s stock valued at $9,392,000 after acquiring an additional 40,992 shares during the period. Calamos Advisors LLC raised its holdings in Incyte Corporation by 37.7% during the 2nd quarter. Calamos Advisors LLC now owns 113,132 shares of the biopharmaceutical company’s stock valued at $14,244,000 after acquiring an additional 30,990 shares during the period. Tredje AP fonden raised its holdings in Incyte Corporation by 63.4% during the 2nd quarter. Tredje AP fonden now owns 22,446 shares of the biopharmaceutical company’s stock valued at $2,826,000 after acquiring an additional 8,706 shares during the period. Finally, Inverness Counsel LLC NY bought a new stake in Incyte Corporation during the 3rd quarter valued at $330,000. 88.85% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently weighed in on INCY shares. Oppenheimer Holdings, Inc. reissued a “hold” rating and issued a $135.00 price objective on shares of Incyte Corporation in a research report on Thursday, August 31st. BMO Capital Markets decreased their target price on Incyte Corporation from $163.00 to $162.00 and set an “outperform” rating for the company in a research report on Thursday, October 26th. Barclays PLC reaffirmed an “overweight” rating and issued a $165.00 target price (down from $180.00) on shares of Incyte Corporation in a research report on Wednesday, August 2nd. Royal Bank Of Canada began coverage on Incyte Corporation in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $136.00 target price for the company. Finally, Raymond James Financial, Inc. raised Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 target price for the company in a research report on Monday, September 11th. Seven research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $144.98.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.